The Rise of Pastilles in Australia: A Game Changer for Medical Cannabis
In recent years, Australia has established itself as a leader in the medical cannabis market, with pastilles becoming a significant player in this transformation. According to the Therapeutic Goods Association (TGA), a notable surge occurred between 2024 and 2025, with pastilles gaining over 25% market share, thus overtaking oils to secure their place as the second most prescribed dosing form. This shift has been revolutionary, driven particularly by companies like Breathe Life Sciences (BLS), which have introduced high-quality products aimed at the needs of patients.
Sam Watson's Vision: Manufacturing Success in Two Markets
After its inception in the UK’s CBD market in 2018, CEO Sam Watson transitioned BLS to Australia to tap into its budding medical cannabis environment. Watson's innovative approach has resulted in remarkable growth. With the establishment of what may be the largest Good Manufacturing Practice (GMP) cannabis gummy production facility, BLS can produce up to three million pastilles monthly, showcasing its ambition to dominate the market. “We were the first company in Australia to launch medicated pastilles, gummies, and we pretty much built that segment in Australia,” he stated proudly.
Bridging Markets: The UK Opportunity
As the pastilles market in Australia flourishes, Watson eyes a similar opportunity in the UK. With the knowledge gained from his successful ventures and a robust production system, he aims to replicate this model across the pond. Leveraging a digital quality management system that minimizes paperwork and enhances efficiency, BLS is well-positioned to break into the UK’s cannabis market. Watson believes that they can not only fill a gap but also pioneer an innovative segment consistent with British consumers' needs.
The Future of Medical Cannabis in the UK: A Vibrant Landscape Awaits
The growing acceptance of cannabis in various formats provides a fertile ground for introduction in the UK. With traditional methods like oils being overshadowed by new alternatives such as pastilles, the landscape is primed for innovation. Watson’s ambition to enrich the UK market with high-quality pastilles comes at a pivotal moment; the medicinal cannabis culture continues evolving, and BLS possesses the unique positioning to influence this journey.
A Community-Centric Approach: Fostering Connections in the Cannabis Sphere
Beyond manufacturing, BLS emphasizes building relationships within the community, engaging stakeholders at every level. By collaborating with local health professionals, educators, and patients, the company seeks to deepen its understanding of consumer desires and improve its offerings. The personal narratives and experiences of community members shape BLS's mission, promising a cannabis landscape that is responsive, inclusive, and continually evolving.
As the UK prepares to welcome this innovative leap, executive cannabis professionals must stay informed and adaptable. The shift from oils to pastilles signifies not just a trend but a change in patient preference and regulatory acceptance. This transition presents opportunities for growth, collaboration, and advancements within the industry.
Write A Comment